Anvisa Approves Kyinsu, First Once-Weekly Insulin–GLP‑1 Fixed‑Dose Combination

Overview

• Anvisa published the registration of Kyinsu in the Diário Oficial da União on Monday, granting Novo Nordisk marketing authorization in Brazil through September 2036.
• Kyinsu combines insulin icodeca, a once-weekly basal insulin analogue, with semaglutide, a GLP‑1 receptor agonist, into a single injectable intended for weekly subcutaneous use.
• The product is labeled for adults with type 2 diabetes who remain uncontrolled on basal insulin or GLP‑1 therapy and is to be used with diet, exercise and other antidiabetic medicines when indicated.
• Anvisa's resolution lists six registered presentations, including pen applicators and cartridges at specified concentrations and some packs that include needles, reflecting different dosing and delivery options.
• The approval could improve dosing convenience and adherence by replacing separate daily injections, but the articles note that commercial launch timing, price and public reimbursement in Brazil remain unreported and will determine real-world access.